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Abstract
Hypoxia plays a critical role in the tumor microenvironment of high-grade gliomas by promoting the glioma stem
cell (GSC)–like phenotype, which displays resistance to standard therapies. We tested three glioblastoma multi-
forme xenograft lines (xenolines) against γ134.5-deleted recombinant oncolytic herpes simplex virus (oHSV) C101
under 1% (hypoxia) and 20.8% (normoxia) oxygen tension for effects on oHSV infectivity, replication, and cyto-
toxicity in all tumor cells and CD133+ GSCs. Expression levels of CD133, a putative GSC marker, and CD111
(nectin-1), an adhesion molecule that is the most efficient method for HSV entry, increased significantly under
hypoxia in all three xenolines. Despite increased CD111 expression under hypoxic conditions, oHSV infectivity,
cytotoxicity and viral recovery were not improved or were diminished in all three xenolines under hypoxia. In contrast,
wild-type HSV-1 equally infected xenoline cells in normoxia and hypoxia, suggesting that the 34.5 mutation plays a role
in the decreased C101 infectivity in hypoxia. Importantly, CD133+ cells were not more resistant to oHSV than CD133−
tumor cells regardless of oxygen tension. Furthermore, CD133 expression decreased as viral dose increased in two of
the xenolines suggesting that up-regulation of CD133 in hypoxia was not the cause of reduced viral efficacy. Our find-
ings that oHSV infectivity and cytotoxicity were diminished under hypoxia in several GBM xenolines likely have
important implications for clinical applications of oHSV therapies, especially considering the vital role of hypoxia in
the microenvironment of GBM tumors.
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Introduction
Intracranial malignant primary brain tumors experience a physiologic
hypoxia with in situ oxygen concentrations typically ranging between
1% and 10%; oxygen tension in most high-grade gliomas is less than
2.5% but can be as low at 0.1% [1–3]. Importantly, hypoxia is a
frequently occurring condition during maintenance and proliferation
of normal neural stem cells—cells that, through acquisition of muta-
tions, are thought to give rise to brain tumor stem cells. These have
been described as a small subpopulation of radiation-resistant and
chemotherapy-resistant cells that are thought to be responsible for
maintaining the neoplastic clone and for tumor recurrence [4–7].
CD133, the most common marker used to identify glioma stem
cells (GSCs), increases significantly in hypoxia, which seems to pro-
mote a more “stem-like” phenotype in glioma cells. Hypoxia is
believed to be a central driver of growth and aggressiveness of human
glial brain tumors in situ, inducing complex survival responses that
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contribute to treatment resistance [8–11]. If not adequately consid-
ered when testing novel therapeutics in vitro, the hypoxic phenotype
may result in a therapeutic effect that is not replicated with tumors
in situ.
One such novel therapy is oncolytic herpes simplex virus (oHSV)
that uses a genetically engineered virus to selectively kill cancer cells
while sparing normal cells. Selectivity is achieved through the dele-
tion of a diploid gene (e.g., the “neurovirulence” gene, γ134.5),
which is essential for replication in quiescent normal cells but is non-
essential for replication in tumor cells [12]. Two different γ134.5-
deleted viruses, G207 and HSV1716, have been used safely in phase
1 trials in patients with recurrent high-grade gliomas [13,14].
Whereas radiographic antitumor activity was demonstrated in a
significant proportion of patients, with some long-term survivors
(>5 years), overall responses were more modest compared with those
seen in earlier in vitro and in vivo murine studies [12,15]. Decreased
viral efficacy because of oxygen tension–induced changes in glioma
cells or GSCs is one potential explanation for this divergence because
in vitro studies have traditionally been performed under normoxic,
high-nutrient conditions.
Recent studies in breast cancer and glioblastoma multiforme
(GBM) cells suggest that hypoxia may enhance oHSV replication
and effectiveness [16,17]. These studies were performed with one
or two established tumor cell lines, which have undergone potent
selection for growth in normoxic, high-nutrient, high-growth factor–
supplemented culture medium over many passages to a point where
they may no longer be representative of their originating tumor. More-
over, there are conflicting data that demonstrate improved oncolysis in
human GBM cell lines in normoxia compared with hypoxia using a
hypoxia-inducible factor–activated HSV [18]. Because of these variabil-
ities, we sought to determine the effect of oxygen tension on oHSV
infectivity, replication, and oncolytic activity and on the ability of
oHSV to infect CD133+ GSCs in a panel of human GBM xenolines
that have never been passaged in tissue culture.
Materials and Methods
Human Glioma Xenolines and Genetically Engineered HSVs
GBM-X12 and GBM-X6 are serially transplantable xenolines
established initially by direct implantation of freshly resected human
GBM tissues into the flanks of immunocompromised athymic nude
(nu/nu) mice. We prefer to call these “xenolines” because these are
established tumor cell lines in mice as opposed to cell lines grown in
culture that are xenografted into mice. These tumors (gift from
C. David James, PhD, and Jann Sarkaria, MD, Mayo Clinic) were
maintained by serial transplantation in athymic nude mice and have
been determined to fit the classic or proliferative molecular subtype
[19,20] (data not shown). GBM-XD456 (gift from Darell D. Bigner,
MD, PhD, Duke University Medical Center) was derived from a
human pediatric frontoparietal GBM, which was directly implanted
into the flank of immunocompromised mice [21]. The molecular
subtype of this tumor was determined to be proneural (data not
shown). Transfer of these tumor samples to the University of Alabama
at Birmingham (UAB) Brain Tissue Core (X050415007), which
provides anonymized coded tissues from properly consented patients,
was approved by the UAB institutional review board. All animal studies
were approved by the UAB Institutional Animal Care and Use Com-
mittee under the animal project number 100608793.
C101, a γ134.5-deleted recombinant virus, has been described
previously [22]. Briefly, the virus was constructed by inserting the
gene-encoding enhanced green fluorescent protein (EGFP) under
the control of the CMV IE promoter in the UL3-UL4 intergenic
region of Δγ134.5 HSV, R3616. Expression of green fluorescent
protein (GFP) was used to distinguish infected and uninfected cells
by fluorescence-activated cell sorter (FACS) analysis. M2001, an
HSV-1 wild-type virus, was constructed by inserting the gene encod-
ing EGFP under the control of the CMV IE promoter in the UL3-
UL4 intergenic regions of wild-type strain F.
Tumor Disaggregation and Tissue Culture
Xenoline tumors were harvested aseptically from the flank of mice
and washed five times with PBS to remove excess blood. Tumors
were separately minced finely with no. 11 scalpel blades and dis-
aggregated in an enzyme solution (5 mg of collagenase I (Worthington
Biochemical Co, Lakewood, NJ), 0.5% trypsin/0.53 mM EDTA
(Invitrogen, Grand Island, NY), 2.5 mg DNAse I (Worthington Bio-
chemical Co) with four to five sequential harvests, pooling cells at each
harvest on ice. Cells were washed twice by centrifugation (200g for
8 minutes at 4°C) in serum-less Dulbecco modified Eagle medium
mixed 50:50 with Ham’s Nutrient Mixture F-12 (Dulbecco modi-
fied Eagle medium/F12; MediaTech, Manassas, VA). Cells were re-
suspended in serum-less NeuroBasal medium (Invitrogen) prepared
with fibroblast growth factor β (Invitrogen) and epidermal growth
factor (Invitrogen) at 10 ng/ml each, 2% B-27 supplement without
vitamin A (Invitrogen), 2 mM L-glutamine, amphotericin B (250 μg/ml),
and gentamicin (50 μg/ml). NeuroBasal medium was used to promote
growth of GSCs and retard their rapid differentiation in response to
wound-fluid-type growth factors (platelet-derived growth factor, trans-
forming growth factor β, etc). Cell cultures were evenly divided andmain-
tained (37°C, 95% humidity, 5% CO2) in either normoxia (20.8%)
or hypoxia (1%) in a BioSpherix hypoxia chamber (Lacona, NY) for
7 days before performing additional studies. All media and solutions
were allowed to equilibrate to the 1% oxygen tension before being
exposed to the cells. All procedures with hypoxic cells were conducted
within the hypoxia chamber, which is fitted with glove ports. Experi-
ments were performed in 1% oxygen tension to recapitulate the severe
hypoxia in high-grade gliomas as demonstrated by Evans et al. [1,2].
Culture medium was exchanged every 3 to 7 days as needed. Character-
istically, xenoline-derived cells in NeuroBasal medium do not attach to
the plastic substratum under either hypoxia or normoxia conditions but
form aggregates of cells, variously termed spheroids, tumorspheres,
or neurospheres.
FACS Analyses
Expression levels of CD133 and CD111 were determined by two-
color FACS on glioma cells cultured for 7 days in normoxia or hypoxia.
Glioma cell spheroids were harvested from culture and dissociated
(37°C, 10-15 minutes) into a single-cell suspension using a solu-
tion of Accutase (Innovative Cell Technologies, San Diego, CA) sup-
plemented with 2.5 μg/ml of DNAse I (Worthington). Cells were
gently triturated with a wide bore pipette to completely dissociate
the spheroids. Cells were filtered through a 40-μm pore Cell Strainer
(BD Biosciences, San Jose, CA) to remove any clumps, washed in
medium, and counted by hemacytometer with trypan blue viability
determination. Viable cells (106) were resuspended in 80 μl of FACS
buffer containing ice-cold PBS with 5% fetal bovine serum, 0.1% of
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sodium azide, and Fc receptor blocking reagent (20 μl; Miltenyi Biotec,
Auburn, CA). Fluorochrome-conjugated monoclonal antibodies were
added: phycoerythrin (PE)–poliovirus receptor–related 1 protein
(PRR1; CD111) (Immunotech, Marseille, France), allophycocyanin
(APC)–CD133 (Miltenyi Biotec). Cells were incubated (10-30 minutes,
4°C), washed twice with iced FACS buffer, and resuspended in 1 ml
of ice-cold PBS with 0.1% sodium azide. Labeled cells were then fixed
in ice-cold fresh 4% paraformaldehyde and then stored in the dark at 4°C
until analysis by the UAB Flow Cytometry Core Facility. Side scatter
versus forward scatter profiles of unstained cells were used to set gates
for each individual xenoline. Data were analyzed using Flow-Jo software
(Tree Star, Inc, Ashland, OR), and results were expressed as a percentage
of gated cells for each cell type identified by antibody binding. Mean
values from multiple determinations were calculated for each xenograft
tested. Paired Student’s t tests were used to determine significance.
In Vitro Infectivity Assay
To determine the ability of a Δγ134.5 recombinant virus or wild-
type virus to infect glioma tumor and GSCs, we dissociated spheroids
cultured in normoxia or 1% hypoxia into a single-cell suspension
(vide supra) and replated 5 × 105 cells/0.8 ml of NeuroBasal medium
in a 12-well flat-bottom plate (Corning Incorporated, Corning, NY).
After overnight culture, C101 or M2001 was added at various multi-
plicities of infection (MOI): 0, 1, 3.3, and 10 plaque-forming units
per cell (PFU/cell) in 200 μl of medium. At 30 hours after infection,
cells and spheroids were collected from each well, dissociated with
Accutase–DNAse I (vide supra) and prepared for FACS analysis with
APC-CD133 and PE-PPR1 monoclonal antibodies. Dead cells were
excluded with SytoxBlue Dead Cell Stain (Invitrogen). Unfixed cells
were tested for expression of GFP, APC, and PE. In a limited number
of studies to assess graded reduction in oxygen tension, cells were
cultured at 3% and 5% hypoxia. Percentages of infected cells at each
level of oxygen tension were normalized to percentages of cells
infected under normoxia (20.8%) at each MOI.
In Vitro Cytotoxicity Assay
Cells cultured in normoxia and hypoxia were dissociated, and
104 cells/well were dispensed into 96-well plates overnight. Graded
doses of C101, ranging from 0 to 100 PFU/cell, were added to each
row. After 72 hours, 25 μl of alamarBlue was added to each well and
incubated for 6 to 8 hours to detect metabolic activity as evidenced by
reduction of the dye from dark blue to pink. Color changes were quan-
tified with a BioTek microplate spectrophotometer (Winooski, VT).
OD595-562nm values were used to calculate numbers of PFU/cell re-
quired to kill 50% of the cells in a 3-day period, an LD50. Whereas
hypoxia may change the extent to which the dye is reduced, each experi-
ment, whether under hypoxia or normoxia, always included a mock-
treated control, to which the extent of dye reduction was normalized for
each experimental condition. Thus, the effect of graded doses ofHSVwas
internally compared with a set of “control” wells that represented 100%
survival of the tumor cells for that set of environmental conditions.
Viral Recovery Assay
Disaggregated xenoline cells (3 × 105) were subjected to normoxic
or hypoxic conditions for 7 days and then infected in parallel with
C101 or M2001 virus at an MOI of 0.1. The virus inocula were
removed after 2 hours and replaced with medium and maintained
under normoxic or hypoxic conditions. At 48 hours after infection,
the infected cultures were frozen (−80°C), and virus recovery from
the normoxic and hypoxic cultures was measured by limiting plaque
dilution on Vero cells as previously described [22].
Statistical Analyses
Student’s t test analyses for significance of mean differences were
performed using Microsoft Excel (Microsoft Corp, Redmond, WA).
P ≤ .05 was considered significant.
Results
CD133 and CD111 Expression
We assessed the percentages of CD133 positivity, a surrogate marker
for GSCs, present in three freshly disaggregated xenolines (GBM-
XD456, GBM-X12, and GBM-X6) in tissue culture under normoxic
and 1% hypoxic environments. Similar to other reports, CD133
expression increased significantly in all three xenolines under hypoxia
(Table 1) [8,9]. GBM-XD456, which had the lowest percentage of
CD133+ cells in normoxia (16.5%), had the greatest relative increase
in CD133 expression (nearly four-fold) under hypoxia. GBM-X6
CD133 expression likewise increased almost three-fold under hypoxia,
whereas GBM-X12, which had the highest CD133% in normoxia
(60.6%), showed only a modest increase in CD133 expression under
hypoxia (76.6%).
Next, we examined CD111 (nectin-1) expression in the xenolines
under normoxia and hypoxia. HSV entry is mediated primarily via
CD111, a cell surface adhesion molecule broadly expressed in epithe-
lial and neuronal cells [23,24]. We have reported that low CD111
expression (<20%) in glioma cells results in ineffective oHSV infec-
tivity and killing [25]. All three cell lines had greater than 40%
expression in normoxia (Table 1). Similar to CD133, CD111 expres-
sion increased significantly in all three xenolines under hypoxic con-
ditions; greater than 60% of cells expressed the HSV entry molecule.
As shown below, this increase in CD111 expression, however, did not
result in improved infectivity or cytotoxicity in any of the xenolines.
Viral Infectivity
To determine whether increased CD111 expression in hypoxia led
to improved oHSV infection, xenoline cells (GBM-XD456, GBM-
X12, and GBM-X6) grown in normoxia and 1% hypoxia were
infected with C101 using serial three-fold MOI concentrations and
the proportion of infected cells were analyzed by FACS at 30 hours.
This time point was chosen to allow the infection process to be well
underway yet before progression to cell death and lysis. The recom-
binant GFP-tagged virus enabled us to discriminate infected and
uninfected individual cells based on CD133 and CD111 expression
detected by multicolor FACS analyses. The highest percentage of
infection was seen in GBM-X12 cells in both normoxia (65.5 ±
Table 1. CD133 and CD111 Expression in Normoxia and Hypoxia.
Xenograft CD133% CD111%
Normoxia Hypoxia P Normoxia Hypoxia P
GBM-XD456 16.5 ± 4.2 64.4 ± 2.1 <.0001 78.9 ± 14.9 88.4 ± 10.8 .03
GBM-X12 60.6 ± 10.5 74.3 ± 6.2 .002 42.8 ± 17.6 60.3 ± 20.0 .02
GBM-X6 26.1 ± 13.0 76.6 ± 4.1 .01 48.9 ± 10.4 78.3 ± 6.4 .0007
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2.0) and hypoxia (48.2 ± 0.8) followed by GBM-XD456. GBM-X6
was the most resistant to oHSV infection with less than 21% of cells
infected at 10 PFU/cell at 30 hours. Importantly, all three xenolines
showed significantly lower infection with C101 in hypoxia compared
with normoxia despite an increase in CD111 expression (Table 2).
Likewise, more CD133+ GSCs were infected in normoxia compared
with hypoxia in each of the xenolines. Similar percentages of CD133−
tumor cells and CD133+ GSCs were infected in either normoxic or
hypoxic conditions with differences in infection ranging from only
0.6% to 4.6%. Whereas the percentage of CD133+ cells infected
was similar to the total percentage of cells infected, the overall propor-
tion of cells that expressed CD133 was significantly decreased in
GBM-X12 and GBM-X6 with increasing viral dose (Figure 1). GBM-
X12 CD133 expression decreased on average from 73.5% ± 1.3% to
49.5% ± 1.3% (P = .0003) in normoxia and 85.2% ± 3.4% to
60.6% ± 1.4% (P = .0005) in hypoxia with increasing virus dose
(0-10 PFU/cell). GBM-X6 CD133 expression similarly fell from
22.0% ± 1.2% to 16.0% ± 0.9% (P = .003) in normoxia and
77.2% ± 8.7% to 59.6% ± 1.4% (P = .009) in hypoxia. No appre-
ciable change in overall CD133 expression was seen with increasing
virus dose in GBM-XD456 in either cell culture condition.
CD111 expression was assessed after infection with increasing MOI
of C101. In all three xenolines, CD111 expression fell significantly
with increasing viral dose and cell infectivity irrespective of oxygen
tension (Figure 2). This was not unexpected because CD111 is down-
regulated after trans-interaction with glycoprotein D [26]. The greatest
drop in CD111 expression was seen in GBM-X12, which also had the
highest percentage of cells infected (71.3% ± 8.4% to 6.1% ± 1.4%
CD111+ in hypoxia and 56.5% ± 0.4% to 1.9% ± 0.5% in normoxia).
The total number of cells infected for each xenoline was less than the
overall percentage of CD111 expression at baseline, suggesting that not
all cells expressing CD111 were infected at 30 hours.
To determine whether the decreased infectivity seen in hypoxia
may be related to the 34.5 deletion, we examined the ability of
wild-type HSV-1 to infect the most resistant xenoline, GBM-X6,
in normoxia and hypoxia. Compared with the 34.5-deleted virus,
the wild-type virus infected significantly more cells in both normoxia
(44.8 ± 5.1 vs 20.4 ± 1.3, P = .002) and hypoxia (48.9 ± 3.4 vs 10.0 ±
0.2, P = .0003). Notably, there was no difference (P = .3) in the ability
of wild-type virus to infect GBM-X6 cells in hypoxia and normoxia,
suggesting that the 34.5 mutation plays a role in the diminished
C101 infectivity in hypoxia.
To establish the effect of the degree of hypoxia on infectivity, dif-
ferences in the percent of cells infected in normoxia and hypoxia at
1%, 3%, or 5% oxygen tension were compared in GBM-X12, the
xenoline having the greatest infectivity differential in normoxia versus
1% hypoxia. Similar percentages of GBM-X12 cells were infected
regardless of the level of hypoxia, suggesting that even mild to mod-
erate hypoxia (5%) limits oHSV infectivity (Figure 3).
Viral Recovery and Cytotoxicity
To confirm our finding that oHSV infection was diminished in
hypoxia, we tested the amount of C101 virus recovered after 48 hours
after infection in each xenoline under both normoxia and hypoxia,
and we measured the cytotoxic effect of C101 72 hours after infec-
tion. The amount of virus recovered was highest in GBM-X12, the
xenoline with the most cells infected, followed by GBM-XD456, and
lowest in GBM-X6 in both normoxia and hypoxia. For GBM-
XD456, significantly more virus was recovered in normoxia compared
with hypoxia (Figure 4). Although there was a trend toward increased
viral recovery in normoxia for GBM-X12, this was not statistically
significant. In GBM-X6, viral recovery was equivalent in normoxia
and hypoxia. Compared with C101, significantly more M2001 virus
was recovered in all three xenolines (Figure 4). Similar to C101,
an equivalent amount of M2001 was recovered in GBM-X12 and
GBM-6 in normoxia and hypoxia, but less virus was recovered in
GBM-XD456 in hypoxia.
Importantly, significantly more cells were killed by C101 in normoxia
compared with hypoxia at multiple-dose levels in GBM-XD456 and
GBM-X12 (Figure 5). No difference in cell killing was seen at any dose
Table 2. Percentage of Total Cells and CD133+ Cells Infected by C101 at 10 PFS/Cell after
30 Hours Based on GFP Expression.
% Infected GBM-XD456 GBM-X12 GBM-X6
Total % infected normoxia 41.5 ± 0.9 65.5 ± 2.0 20.4 ± 1.3
Total % infected hypoxia 26.4 ± 0.9 48.2 ± 0.8 10.0 ± 0.2
P <.0001 .002 .0001
CD133+ % infected normoxia 42.1 ± 1.6 61.3 ± 1.7 15.8 ± 0.9
CD133+ % infected hypoxia 27.7 ± 0.8 44.1 ± 1.2 7.5 ± 0.1
P .0007 .006 <.0001
Figure 1. Percentage of cells expressing CD133 at various MOI 30 hours after infection in normoxia or hypoxia. The percentage of total
cells expressing CD133 decreased significantly in GBM-X6 and GBM-X12 with increasing viral doses in both normoxia (dotted lines) and
hypoxia (solid lines), whereas no appreciable change in CD133 expression was observed in GBM-XD456.
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level in normoxia compared with hypoxia in GBM-X6. The lethal dose
of C101 required to kill 50% of the cells (LD50) was lowest in GBM-
X12 and highest in GBM-X6 in both normoxia and hypoxia. This was
consistent with both the infectivity and viral recovery data, which
demonstrated that GBM-X12 was the most sensitive and GBM-X6
was the most resistant xenoline. Significantly higher doses of C101 were
required to kill 50% of the cells in hypoxia compared with normoxia for
GBM-XD456 (10.7 ± 0.8 vs 7.0 ± 2.0 PFU/cell, P = .04) and GBM-
X12 (3.2 ± 0.2 vs 1.9 ± 0.1 PFU/cell, P = .006). A 52.9% and 68.4%
higher dose in hypoxia was required to kill the same number of cells as in
normoxia, respectively. Although a higher dose of GBM-X6 was also
required in hypoxia (47.1 ± 2.9 vs 44.8 ± 3.0 PFU/cell), this was not
statistically significant (P = .36). Taken together, these data demonstrate
that oHSV infectivity and cytotoxicity in GBM xenolines is not
enhanced by hypoxia, and in fact, hypoxia may diminish efficacy.
Discussion
Gliomas experience a physiologic hypoxia with hypoxic gradients
within tumors ranging from mild (10%) to moderate (2.5%) to
severe (0.1%), which tends to mark regions of necrosis [1]. High-
grade tumors contain more areas of moderate to severe hypoxia com-
pared with low-grade gliomas [2,3]. Hypoxia plays a critical role in
the tumor microenvironment of high-grade gliomas [1–3]. Recent
evidence suggests that hypoxia is involved in GBM development,
invasion, induction of angiogenesis, loss of apoptotic potential, and
resistance to chemotherapy and radiation [27]. Moreover, the degree
of hypoxia correlates with a more clinically aggressive phenotype and
more rapid tumor recurrence [2]. Many of these features that make
GBM tumors so difficult-to-treat may well be attributed to hypoxia’s
effect on promoting the GSC phenotype. Recently, oHSV was dem-
onstrated to be efficacious against GSCs under normoxic conditions
in vitro [25,28]. This novel, targeted therapy has been successfully
translated to clinical trials, and new trials are forthcoming with “second-
generation” viruses that were more effective in animal studies than
the viruses previously used in human studies. As next-generation
viruses are created, an understanding of hypoxia’s effect on oHSV
infectivity and replication in tumor cells and GSCs will be critical
to ensure the most beneficial viruses make it to clinical trials. We chose
to conduct studies to determine oHSV efficacy in vitro at 1% oxygen
tension, the lower limit of cell viability, to model the most stringent
hypoxic cellular microenvironment in which cells live in high-grade
gliomas because these areas seem to be critical to the overall aggressive-
ness and therapeutic resistance of these tumors. Mutant HSV must be
able to infect and replicate in cells under this harsh environment to be
most effective.
HSV enters mammalian cells both through direct cell membrane
fusion and through endocytosis. HSV has broad cellular tropism
involving the interaction of multiple HSV glycoproteins with cellular
surface receptors. The process follows three stages: 1) binding or
tethering, 2) triggering, and 3) fusion of the membranes [29]. The
Figure 3. Percentage of infected cells based on GFP expression at
three different oxygen tensions. Results were normalized to the
percentage of cells infected under normoxia (20.8% O2) at each
MOI. There were no significant differences in the percentages of
GBM-X12 cells infected regardless of the severity of hypoxia
(≤5% O2).
Figure 4. C101 (34.5-deleted) and M2001 (wild-type) virus recovery
at 48 hours after infection with 0.1 PFU/cell. Significantly more
M2001 virus was recovered than C101 in all xenolines tested. In
GBM-XD456, significantly less C101 and M2001 virus were recov-
ered in hypoxia compared with normoxia.
Figure 2. Percentage of cells expressing CD111 at various MOI
30 hours after infection in normoxia and hypoxia. CD111 expres-
sion decreased significantly with increasing viral doses in all three
xenografts tested in both normoxia and hypoxia.
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first step in oHSV infection is virus entry, which is primarily medi-
ated in glioma cells by the adhesion molecule CD111 (nectin-1).
CD111 and CD112 (nectin-2) are one of three recognized classes
of cell membrane receptors important for HSV-1 entry, along with
herpes virus entry mediator and heparan sulfate proteoglycan, which
is believed to be ubiquitously expressed [24,29,30]. Herpes virus
entry mediator, a member of the tumor necrosis factor receptor fam-
ily, is mainly expressed on T and B lymphocytes and not neuroglial
cells to a significant degree. Whereas CD111 and CD112 (nectin-2)
are expressed in a variety of tissues including neuronal cells, CD112
is more important for HSV-2 entry. CD111 is the most efficient
method for HSV-1 virus entry, and its expression level predicts sen-
sitivity to oHSV in several tumor types including thyroid cancer,
squamous cell carcinoma, and other invasive carcinomas [24,31–33].
In brain tumors, Rueger et al. [34] found that, whereas only tumor cells
that expressed CD111 were transducible with an HSV-1 amplicon
vector, not all cells expressing CD111 were transduced. Previously,
we showed variable infectability of glioma xenolines without a direct
correlation between CD111 expression and oHSV infectivity and cyto-
toxicity; however, we demonstrated that oHSV was unable to efficiently
enter and therefore infect and kill glioma xenolines with low (<20%)
CD111 expression [25].
In this report, one novel finding was the increased expression of
CD111 in GBM xenolines under hypoxia. Koike et al. [35] showed
that several cell adhesion molecules, like CD111, are induced by
hypoxia in colon cancer cells and result in enhanced adhesion to
vascular endothelial cells, which may facilitate tumor angiogenesis.
The up-regulation of CD111 in hypoxia may play a similar role in
GBM tumors. Paradoxically, despite the increased CD111 expression
under hypoxic conditions, oHSV infectivity, cytotoxicity, and viral
recovery were diminished in several xenolines. Moreover, GBM-
X12, the tumor with the lowest CD111 expression in both normoxia
and hypoxia, was the most efficiently killed by oHSV. This suggests
that a minimum level of CD111 is necessary for a productive infec-
tion, but other cellular factors can limit oHSV infectivity, even if
there are ample entry molecules. Furthermore, these data suggest that
other less efficient mechanisms of cell entry are used in sensitive tumors
with lower CD111 expression. It is important to note that whereas
approximately 40% of GBM-X12 cells were considered negative with
regard to fluorescence threshold for detection in FACS analysis, these
cells may express CD111 to a limited extent that may enable infection.
As might be expected when oHSV enters and infects a cell, we observed
that CD111 expression was lost. This likely represents the internaliza-
tion or change in the conformation of the molecule as a function of
oHSV entry and viral gene expression [26].
Similar to others, we found CD133 expression increased signifi-
cantly under hypoxia. Importantly, the CD133+ fraction was infected
in similar proportions to all tumor cells regardless of oxygen tension,
confirming our earlier findings that CD133+ cells are as sensitive to
oHSV as other tumor cells and that oHSV may be an attractive ther-
apy to eradicate difficult to treat GSCs. Similar to all tumor cells,
CD133+ GSC infectivity was enhanced in normoxia. Moreover,
CD133 expression declined in two of the three xenolines with increas-
ing viral doses. The mechanism of this novel finding is unknown and
requires further study. Because we previously showed that CD133+
and CD133− cells are similarly killed by various oHSVs, it is unlikely
that the virus selectively kills the CD133+ cells in greater proportions
to CD133− cells [25]. Thus, the significance of this phenomenon
remains to be determined with regard to the overall efficacy of onco-
lytic virotherapy. One possible explanation is that CD133+ cells are
more fragile and die faster or undergo apoptosis at a more rapid rate
than CD133− cells. However, given the modulation of the cell
membrane by virus entry, a more likely explanation is that the con-
formation of the CD133 molecule is being altered or that CD133 is
being internalized or its expression downregulated. HSV is able to
modify the autophagic and apoptotic properties of cells under stress
from infection so that the virus may complete its life cycle [36].
Because CD133 expression is known to be regulated by bioenergetic
stress, it is possible that the virus is interfering with cellular response
to stress resulting in a change to the cellular phenotype and down-
regulation of CD133 [37]. Whether this decrease in CD133 expression
actually alters the “stem cell–like” properties of the glioma cell requires
further investigation.
Notably, hypoxia decreased or did not enhance oHSV infectivity,
viral replication, and cytotoxicity in all three xenolines tested, whereas
wild-type HSV-1 infectivity was not limited by hypoxia. A similar
percentage of GBM-X12 cells were infected at 1%, 3%, and 5%
oxygen tension, suggesting that the decreased infectivity is not limited
to severe hypoxic conditions but also occurs at more modest degrees of
hypoxia. These findings are likely clinically significant and strongly
suggest that oxygen tension must be considered when preparing
next-generation viruses for clinical application. Understanding the
mechanism(s) behind the decreased viral efficacy in hypoxia will
be important for the development of more effective viruses that
Figure 5. Sensitivity of GBM-XD456 and GBM-X12 to C101 in hypoxia versus normoxia. Results were measured by the alamarBlue assay
at a given MOI compared with a control (no virus) after a 3-day incubation period. GBM-XD456 and GBM-X12 cells were more sensitive
to killing in normoxia (dotted lines) compared with hypoxia (solid lines) at several different MOIs. The lethal dose required to kill 50% of
cells was significantly lower in normoxia in GBM-XD456 and GBM-X12.
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can evade the mechanism(s) or limit the effects. The decreased GFP
expression seen under hypoxia in the infectivity assay suggests that
the effect on the virus occurs early because GFP is produced along
with early viral genes.
There are many potential mechanisms that require investigation
including, but not limited to, reduced viral entry or transport, enhanced
activation of antiviral host cell response(s), increased autophagy, and
limited infected cell polypeptide 0 (ICP0) protein production or activ-
ity. Although hypoxia increases expression of CD111, it may alter
the conformation of the adhesion molecule such that HSV entry is
impeded. Alternatively, the low-energy hypoxic conditions may pre-
clude efficient fusion of the viral envelope with the cell membrane or
actin-dependent intracellular transport of the virus. Once the virus
has entered the cell, hypoxia may augment the activation of antiviral
host cell responses, which occurs in three phases: sensitization, induc-
tion, and amplification [38]. Sensitization involves phosphorylation of
interferon-regulatory factor 3 (IRF3), which upregulates expression of
interferon β1. Recently, hypoxia has been shown to enhance IRF3
activation in microglia cells [39]. Interferon β1 activates signal trans-
ducers and activators of transcription family of proteins which results
in production of interferon α in the induction phase. In breast cancer
cells, Lee et al. [40] demonstrated that hypoxia is a critical stimulator for
activation of signal transducers and activators of transcription proteins.
The amplification phase consists of increased production of antiviral
proteins including protein kinase R (PKR), which results in translation
inhibition in the infected cell to limit viral replication. Hypoxia may
increase production of PKR, a known regulator of hypoxia-inducible
factor 1α, thereby decreasing efficacy of oHSV [41]. PKR is positioned
upstream of Beclin-1, an autophagy protein that the γ134.5 gene prod-
uct (ICP34.5) binds to confer neurovirulence [42]. Recently, Song
et al. [43] demonstrated that decreased hepatocellular carcinoma cell
death in hypoxia was mainly attributed to decreased apoptosis, which
was dependent on Beclin-1 activity. Thus, the γ134.5-deleted virus may
be limited by autophagy in hypoxia. Lastly, ICP0 (product of the HSV-
1 α0 gene) plays a critical role in HSV infection by inactivating and
disrupting host cell antiviral responses [44]. If ICP0 expression is
decreased or blocked in hypoxia, HSV replication would be decreased.
Our result that hypoxia decreased oHSV efficacy is different from
that reported in one previous study involving the U87 glioma cell
line [16]. A trivial explanation is that our in vitro studies used three
different short-term in vivo passaged human gliomas that were never
cultured long term, in contrast to U87-MG, which has been in almost
continuous normoxic tissue culture because it was established in the
late 1960s by Dr Jan Ponten. Thus, these long-term cultured glioma
cells may be quite distinct from the glioma xenolines in many respects,
given entirely different selection pressures. Another distinction lies in
the basic experimental design that could account for the differences;
for example, this could be virus dose related in that a single dose of
0.4 MOI was used in the U87 cells, whereas we used three larger
doses (1, 3.3, and 10 MOI) in our infectivity assays and five higher
doses (1-100 MOI) in our cytotoxicity assays. Moreover, our defined
“stem cell” culture medium did not contain fetal bovine serum and the
entire hypoxic culture procedure and infection manipulations were
performed within a BioSpherix hypoxia chamber with glove ports that
enclosed a Forma CO2 incubator within the workspace maintained at a
constant oxygen tension. Only after the cells were fixed in the hypoxia
chamber were any procedures performed under normal atmospheric
conditions. Our observation has been that only a brief exposure to
20.8% oxygen is necessary to activate an entirely distinct transcriptomic
response in cells that have been maintained under hypoxia. Another
possible distinction is that the U87 cell line may contain unique features
such as the up-regulation of GADD34, which promoted virus replica-
tion under lower oxygen tension. We have not examined GADD34
expression in our three GBM-X lines.
Our findings that oHSV infectivity and cytotoxicity are dimin-
ished under hypoxia in several GBM xenolines likely have important
implications for future oHSV-based clinical trials, especially consid-
ering the vital role of hypoxia in the microenvironment of GBM
tumors. The impact of oxygen tension must be considered when test-
ing “next-generation” viruses in vitro. Strategies that may be used to
enhance oHSV efficacy in hypoxia include viruses that disrupt the
microenvironment through protein production, create an enhanced
immune response through cytokine production, or preferentially rep-
licate in hypoxic areas through a hypoxia-responsive promoter
[18,45,46]. Further studies will be necessary to examine the efficacy
of oHSV in hypoxic areas of GBM xenolines in vivo and to deter-
mine mechanisms resulting in decreased efficacy of oHSV in hypoxic
conditions so that these mechanisms may be circumvented by further
manipulation of the virus genome, if possible.
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